CD274 and non-small cell lung carcinoma: Intriguingly, antiangiogenic therapy appears to counteract the pro-angiogenic factors stimulated by PD-L1, particularly through the STAT signaling pathway in NSCLC cell lines (Cavazzoni et al., 2024).